Changes of HbA1c from baseline to 40 week were -1.3 %, -1.7 %, -1.7 % and -0.8 % with orforglipron 3 mg, 12 mg and 36 mg and dapagliflozin, respectively -5 is a Phase 3, 40-week, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of orforglipron 3 mg, 12 mg and 36 mg in participants with type 2 diabetes and inadequate glycemic control with insulin glargine, with or without metformin and/or SGLT-2 inhibitors
Stomach motility that is slowed by a GLP-1 drug will typically return to normal once the individual stops taking the drug
Furman leans closer to the maybe not side: Whereas salty, sugary snacks used to be a preference, people on these drugs now are interested in low-sugar, no-sugar, protein-rich and nutrient-dense snacks, she said
This is supported by the inclusion of Wesley Nicolas, an in-house counsel at Novo Nordisk, among the top listed representatives
Ideal candidates include adults with a body mass index (BMI) 30 kg/m or 27 kg/m with at least one weight-related comorbidity, such as hypertension or type 2 diabetes (Wilding et al., 2021)
A healthy diet not only supports weight management, but also contributes to overall well-being and disease prevention
